Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
Shared Decision Making for Patients With First-admission Schizophrenia
To determine whether shared decision making (SDM) intervention improves patient satisfaction in patients with first-admission schizophrenia compared with usual care.
- Trial name
- NCT01869660
- Testing
- Shared Decision Making
- Where
- Japan
- Volunteers
- 23 people
- Sponsor
- Yokohama City University
Schizophrenia
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
- Trial name
- NCT06799559
- Testing
- 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Dyslipidemias
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients.
- Trial name
- NCT04761861
- Testing
- Vildagliptin 50 MG
- Where
- Egypt
- Sponsor
- Sadat City University
Schizophrenia
A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects.
- Trial name
- NCT02174510
- Testing
- 20mg lurasidone, 40mg lurasidone, 80mg lurasidone
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia, Schizophrenic Disorders
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
augmentation of clozapine with paliperidone in the treatment of resistant schizophrenia has not been tested until now in randomized controlled trials.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorder
- Trial name
- NCT01279213
- Testing
- paliperidone clozapine
- Where
- Argentina
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Rosario
Schizophrenia, Schizoaffective Disorder
Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia
This research investigates the benefits of productive activity and cognitive rehabilitation for patients with schizophrenia. Key questions are: 1.
- Trial name
- NCT00430560
- Testing
- cognitive rehabilitation, work therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Diabetes
Medication Reviews in Severe Mental Illness
This study aims to investigate the potential beneficial effects of a medication review by a clinical pharmacologist on patients with coexisting severe mental illness and diabetes.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Severe Mental Disorder
- Trial name
- NCT05243160
- Testing
- medication review
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Schizophrenia
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who…
- Trial name
- NCT01515423
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 174 sites in United States, Argentina and 24 more
- Volunteers
- 1,429 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: how the body processes (uses) glucose (blood sugar) how much…
- Trial name
- NCT05463770
- Testing
- SEP-363856
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Anodal Stimulation tDCS, Schizophrenia
Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia
Impairments of cognition are a core, severely disabling feature of schizophrenia leading to poor long-term outcome with no established treatment available.
- Conditions
- Anodal Stimulation tDCS, Schizophrenia, Working Memory
- Trial name
- NCT02823639
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in Germany
- Volunteers
- 128 people
- Sponsor
- University Hospital Tuebingen
Schizophrenia and Schizophrenia Spectrum Psychosis
Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia
Patients suffering from schizophrenia and schizophrenia spectrum psychosis frequently experience cognitive impairments. Such deficits may affect memory, attention and executive function processes.
- Trial name
- NCT00314639
- Testing
- modafinil
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Schizophrenia, Schizoaffective Disorder
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
The investigators propose to recruit individuals with schizophrenia who are symptomatically stable and already taking medications to participate in this study.
- Trial name
- NCT01519557
- Testing
- DAR-100A
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- New York State Psychiatric Institute
Psychosis, Schizophrenia
State Representation in Early Psychosis
The purpose of this study is to examine state representation in individuals aged 15-45 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis.
- Conditions
- Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
- Trial name
- STEP (NCT05273164)
- Where
- United States
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Severe Mental Disorder, Schizophrenia
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia
To contribute to improving the level of functioning and quality of life and mental health outcomes for people with severe and enduring mental ill health (SMI) (schizophrenia, bipolar disorder, depression) by adapting and up…
- Conditions
- Severe Mental Disorder, Schizophrenia, Bipolar Disorder, Severe Depression
- Trial name
- RECOVER-E (NCT03862209)
- Testing
- Community mental health team
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- Klinički Bolnički Centar Zagreb
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846881
- Testing
- Iclepertin
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 611 people
- Sponsor
- Boehringer Ingelheim
Psychotic Disorders
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders
- Trial name
- NCT00224302
- Testing
- Duloxetine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Schizoaffective Disorder
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive…
- Trial name
- NCT06003036
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Deepak K. Sarpal, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.